Birmingham, AL Clinical Trials Report — April 2026

For Birmingham residents exploring clinical trial options, April 2026 presents a timely opportunity, especially with 69 trials slated to conclude enrollment within the next 90 days. Of these, 15 are still actively seeking healthy volunteers, offering a chance to contribute to medical research without a specific health condition. Individuals interested in participating should review these options promptly.

New Opportunities for Healthy Volunteers

This month, 5 of the 12 new trials launched in Birmingham are accepting healthy volunteers, adding to the 121 total trials currently recruiting participants without specific health conditions. These studies offer a valuable way to contribute to medical science, often focusing on understanding normal body functions or testing new diagnostic methods.

Spotlight on Notable New Research

April brings several significant new trials to Birmingham, including important Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across various health challenges.

• Novo Nordisk A/S is sponsoring NCT07533175, "AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight." This Phase 3 study aims for 630 participants and will evaluate the safety and effectiveness of NNC0487-0111, administered as a weekly injection, for individuals with excess body weight and type 2 diabetes.
• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This crucial Phase 3 oncology trial seeks 588 participants to assess the efficacy and safety of a new combination therapy for metastatic pancreatic cancer.
• Mead Johnson Nutrition is sponsoring NCT07513506, "Extensively Hydrolyzed Formula Growth Monitoring Study (GMS)." This study, designed for 214 participants, compares an investigational infant formula against a currently marketed formula to evaluate growth outcomes.
• Eccogene is initiating NCT07505303, "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial." This Phase 2 study, targeting 160 participants, will evaluate the effect of oral ECC4703 on body weight reduction and liver fat content.
• The University of Alabama at Birmingham is leading NCT07521657, "Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma." This Phase 2, open-label study involving 55 participants investigates mirdametinib in combination with radiation for various forms of glioma.
• Sano Chemicals Inc is sponsoring NCT07521137, "Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence." This Phase 2a randomized, double-blind, placebo-controlled study with 36 participants evaluates the safety, tolerability, and efficacy of OCF001 intravaginal gel for acute vulvovaginal candidiasis.

Birmingham's Leading Research Facilities

Birmingham is a significant hub for clinical research in Alabama, with 939 trials currently recruiting across 340 research facilities. The city's top institutions consistently lead in the volume of active studies, making them key destinations for individuals interested in participation:

• University of Alabama at Birmingham (290 trials)
• University of Alabama at Birmingham Cancer Center (57 trials)
• Children's Hospital of Alabama (41 trials)
• University of Alabama (27 trials)
• University of Alabama Birmingham (26 trials)
• Research Site (22 trials)
• The University of Alabama at Birmingham (21 trials)
• Children's of Alabama (16 trials)
• UAB (13 trials)
• University of Alabama Hospital (10 trials)
• Birmingham VA Medical Center, Birmingham, AL (9 trials)
• Central Alabama Research (8 trials)

The University of Alabama at Birmingham and its associated centers are clearly the dominant force in local research, offering a wide array of studies across many medical specialties.

Trials Closing Soon by Condition

For patients managing specific health conditions, several trials are nearing their enrollment deadlines. Conditions with trials closing within the next 90 days include:

• Acute kidney injury (2 trials)
• Atopic dermatitis (2 trials)
• Acute respiratory distress syndrome (1 trial)
• Aged (1 trial)
• Amputation, traumatic/surgery (1 trial)
• Amputation, wound (1 trial)
• Anatomic stage ii breast cancer ajcc v8 (1 trial)
• Amyotrophic lateral sclerosis (1 trial)
• Anatomic stage iii breast cancer ajcc v8 (1 trial)
• Aortic aneurysm (1 trial)

Overview of New Trials This Month

This April, Birmingham saw 12 new trials open, a slight increase from the 11 that opened in March 2026. This trend continues to demonstrate a steady pace of new research opportunities in the city. The new trials cover a diverse range of conditions, including acellular dermal matrix, adult obesity, alveolar mucosa, brain fog, candidiasis, vulvovaginal, chronic fatigue, chronic fatigue syndrome (cfs), cognitive dysfunction, cognitive impairment, and congenital anomaly.

By type, 5 of the new trials are drug studies, 3 involve procedures, 2 are behavioral interventions, and others include dietary supplements, combination products, and devices. The University of Alabama at Birmingham is a prominent sponsor of new research this month, leading 6 of the new trials. Other notable sponsors include Incyte Corporation, Mead Johnson Nutrition, Eccogene, Occlutech International AB, Sano Chemicals Inc, and Novo Nordisk A/S.

Eligibility for these new studies is broad, with 3 trials including children and 11 specifically including older adults. One new trial is exclusively for female participants.

Exploring Opportunities in Nearby Cities

While Birmingham offers a robust selection of clinical trials, residents may also find opportunities in nearby Alabama communities. Both Gardendale and Hoover currently have 1 active trial each, providing additional options for those willing to travel a short distance for participation.

As we move further into spring, Birmingham's research community continues to drive medical innovation, offering diverse opportunities for individuals to contribute to health advancements. Keep an eye on new developments as researchers continue to explore novel treatments and prevention strategies.